Becton, Dickinson and Company (BDX) to Issue Quarterly Dividend of $1.05 on December 31st

by · The Cerbat Gem

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) declared a quarterly dividend on Thursday, November 6th. Stockholders of record on Monday, December 8th will be given a dividend of 1.05 per share by the medical instruments supplier on Wednesday, December 31st. This represents a c) dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Monday, December 8th. This is a 1.0% increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04.

Becton, Dickinson and Company has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 53 years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Becton, Dickinson and Company to earn $15.64 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 26.9%.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $193.92 on Friday. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The business has a 50-day moving average price of $188.28 and a 200 day moving average price of $183.73. The company has a market capitalization of $55.35 billion, a P/E ratio of 33.26, a PEG ratio of 1.79 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The business had revenue of $5.32 billion for the quarter. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Analysts Set New Price Targets

BDX has been the subject of a number of recent research reports. Argus boosted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Jefferies Financial Group dropped their price objective on Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday, November 7th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Finally, Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $204.45.

View Our Latest Research Report on Becton, Dickinson and Company

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories